Apaziquone for Nonmuscle Invasive Bladder Cancer: Where Are We Now?

Urol Clin North Am. 2020 Feb;47(1):73-82. doi: 10.1016/j.ucl.2019.09.009.

Abstract

Apaziquone is an interesting drug for intravesical use in patients with nonmuscle invasive bladder cancer; however, more research is needed to prove its actual benefit. Although the apaziquone trials demonstrate the potential of this new drug, the singular phase 3 trials did not reach their primary endpoint. To date, no new trials are recruiting, so the development of apaziquone seems to have stopped.

Keywords: Apaziquone; Bladder cancer; Experimental; Nonmuscle invasive; Therapy.

Publication types

  • Review

MeSH terms

  • Administration, Intravesical
  • Antineoplastic Agents / administration & dosage
  • Aziridines / administration & dosage*
  • Carcinoma, Transitional Cell / drug therapy*
  • Carcinoma, Transitional Cell / pathology
  • Humans
  • Indolequinones / administration & dosage*
  • Neoplasm Invasiveness
  • Treatment Outcome
  • Urinary Bladder Neoplasms / drug therapy*
  • Urinary Bladder Neoplasms / pathology

Substances

  • Antineoplastic Agents
  • Aziridines
  • Indolequinones
  • apaziquone